Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4799-4811

  Betancor, Gilberto ^a   Puertas, Maria C ^b   Nevot, María ^b   Garriga, César ^a,c   Martínez, Miguel A ^b   Martinez Picado, Javier ^b,d   Menéndez Arias, Luis ^a  

^a CSIC   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CARBOVIR; DIDANOSINE; DNA; LAMIVUDINE; PHOSPHATE; RIBONUCLEASE H; RNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DNA TEMPLATE; ENZYME ACTIVITY; ENZYME KINETICS; EQUILIBRIUM CONSTANT; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; TREATMENT FAILURE; VIRUS REPLICATION; WILD TYPE;

CELL LINE; CELLS, CULTURED; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; VIRUS REPLICATION; ZIDOVUDINE;

EID: 78049269916     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00716-10     Document Type: Article

References (75)

1. Álvarez, M., T. Matamoros, and L. Menéndez-Arias. 2009. Increased thermostability and fidelity of DNA synthesis of wild-type and mutant HIV-1 group O reverse transcriptases. J. Mol. Biol. 392:872-884.
2. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15917.
3. Basavapathruni, A., and K. S. Anderson. 2007. Reverse transcription of the HIV-1 pandemic. FASEB J. 21:3795-3808.
4. Bebenek, K., W. A. Beard, J. R. Casas-Finet, H.-R. Kim, T. A. Darden, S. H. Wilson, and T. A. Kunkel. 1995. Reduced frameshift fidelity and processivity of HIV-1 reverse transcriptase mutants containing alanine substitutions in helix H of the thumb subdomain. J. Biol. Chem. 270:19516-19523.
5. Bebenek, K., W. A. Beard, T. A. Darden, L. Li, R. Prasad, B. A. Luxon, D. G. Gorenstein, S. H. Wilson, and T. A. Kunkel. 1997. A minor groove binding track in reverse transcriptase. Nat. Struct. Biol. 4:194-197.
6. Betancour, G., M. C. Puertas, M. Nevot, C. Garriga, M. A. Martínez, J. Martinez-Picado, and L. Menéndez-Arias. 2010. Mechanisms of nucleoside analogue resistance associated with the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms. Antivir. Ther. 15(Suppl. 2):A80.
7. Boretto, J., S. Longhi, J.-M. Navarro, B. Selmi, J. Sire, and B. Canard. 2001. An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase. Anal. Biochem. 292:139-147.
8. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:4832-4842.
9. Brehm, J. H., J. W. Mellors, and N. Sluis-Cremer. 2008. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 47:14020-14027.
10. Cane, P. A., H. Green, E. Fearnhill, and D. Dunn, on behalf of the UK Collaborative Group on HIV Drug Resistance. 2007. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 21:447-455.
11. Cases-González, C. E., S. Franco, M. A. Martínez, and L. Menéndez-Arias. 2007. Mutational patterns associated with the 69 insertion complex in multidrug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. J. Mol. Biol. 365:298-309.
12. Ceccherini-Silberstein, F., V. Svicher, T. Sing, A. Artese, M. M. Santoro, F. Forbici, A. Bertoli, S. Alcaro, G. Palamara, A. d'Arminio Monforte, J. Balzarini, A. Antinori, T. Lengauer, and C. Perno. 2007. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J. Virol. 81:11507-11519.
13. De Clercq, E., and J. Neyts. 2009. Antiviral agents acting as DNA or RNA chain terminators. Handb. Exp. Pharmacol. 189:53-84.
14. Delviks-Frankenberry, K. A., G. N. Nikolenko, R. Barr, and V. K. Pathak. 2007. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J. Virol. 81:6837-6845.
15. Delviks-Frankenberry, K. A., G. N. Nikolenko, P. L. Boyer, S. H. Hughes, J. M. Coffin, A. Jere, and V. K. Pathak. 2008. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. U. S. A. 105:10943-10948.
16. Deval, J., J.-M. Navarro, B. Selmi, J. Courcambeck, J. Boretto, P. Halfon, S. Garrido-Urbani, J. Sire, and B. Canard. 2004. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J. Biol. Chem. 279:25489-25496.
17. Ding, J., K. Das, Y. Hsiou, S. G. Sarafianos, A. D. Clark, Jr., A. Jacobo-Molina, C. Tantillo, S. H. Hughes, and E. Arnold. 1998. Structural and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J. Mol. Biol. 284:1095-1111.
18. Dunn, L. L., M. J. McWilliams, K. Das, E. Arnold, and S. H. Hughes. 2009. Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions. J. Virol. 83:12336-12344.
19. Ehteshami, M., G. L. Beilhartz, B. J. Scarth, E. P. Tchesnokov, S. McCormick, B. Wynhoven, P. R. Harrigan, and M. Götte. 2008. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms. J. Biol. Chem. 283:22222-22232.
20. Felsenstein, J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39:783-791.
21. Garriga, C., M. J. Pérez-Elías, R. Delgado, L. Ruiz, L. Pérez-Álvarez, T. Pumarola, A. López-Lirola, J. González-García, and L. Menéndez-Arias, on behalf of the Spanish Group for the Study of Antiretroviral Drug Resistance. 2009. HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations. J. Antimicrob. Chemother. 64:251-258.
22. Hachiya, A., E. N. Kodama, S. G. Sarafianos, M. M. Schuckmann, Y. Sakagami, M. Matsuoka, M. Takiguchi, H. Gatanaga, and S. Oka. 2008. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 82:3261-3270.
23. Hermann, T., T. Meier, M. Götte, and H. Heumann. 1994. The 'helix clamp' in HIV-1 reverse transcriptase: a new nucleic acid binding motif common in nucleic acid polymerases. Nucleic Acids Res. 22:4625-4633.
24. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
25. Huigen, M. C., P. M. van Ham, L. de Graaf, R. M. Kagan, C. A. Boucher, and M. Nijhuis. 2008. Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase. Retrovirology 5:20.
26. Isel, C., C. Ehresmann, P. Walter, B. Ehresmann, and R. Marquet. 2001. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J. Biol. Chem. 276:48725-48732.
27. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. U. S. A. 90:6320-6324.
28. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997.
29. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
30. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
31. Lu, L., J. Whitcomb, and D. R. Kuritzkes. 2005. Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness. J. Acquir. Immune Defic. Syndr. 40:20-23.
32. Marchand, B., K. L. White, J. K. Ly, N. A. Margot, R. Wang, M. McDermott, M. D. Miller, and M. Götte. 2007. Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir. Antimicrob. Agents Chemother. 51:2911-2919.
33. Mas, A., M. Parera, C. Briones, V. Soriano, M. A. Martínez, E. Domingo, and L. Menéndez-Arias. 2000. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J. 19:5752-5761.
34. Mas, A., B. M. Vázquez-Álvarez, E. Domingo, and L. Menéndez-Arias. 2002. Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J. Mol. Biol. 323:181-197.
35. Matamoros, T., J. Deval, C. Guerreiro, L. Mulard, B. Canard, and L. Menéndez-Arias. 2005. Suppression of multidrug-resistant HIV-1 reverse transcriptase primer unblocking activity by α-phosphate-modified thymidine analogues. J. Mol. Biol. 349:451-463.
36. Matamoros, T., S. Franco, B. M. Vázquez-Álvarez, A. Mas, M. A. Martínez, and L. Menéndez-Arias. 2004. Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers. J. Biol. Chem. 279:24569-24577.
37. Matamoros, T., M. Nevot, M. A. Martínez, and L. Menéndez-Arias. 2009. Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase. Effects of substituting valine 75 on stavudine excision and discrimination. J. Biol. Chem. 284:32792-32802.
38. Menéndez-Arias, L. 1998. Studies on the effects of truncating α-helix E′ of p66 human immunodeficiency virus type 1 reverse transcriptase on templateprimer binding and fidelity of DNA synthesis. Biochemistry 37:16636-16644.
39. Menéndez-Arias, L. 2008. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 134:124-146.
40. Menéndez-Arias, L. 2010. Molecular basis of human immunodeficiency drug resistance: an update. Antiviral Res. 85:210-231.
41. Menéndez-Arias, L., A. Abraha, M. E. Quiñones-Mateu, A. Mas, M.-J. Camarasa, and E. J. Arts. 2001. Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains. J. Biol. Chem. 276:27470-27479.
42. Meyer, P. R., S. E. Matsuura, A. M. Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:35-43.
43. Meyer, P. R., S. E. Matsuura, R. F. Schinazi, A. G. So, and W. A. Scott. 2000. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 44:3465-3472.
44. Meyer, P. R., S. E. Matsuura, A. A. Tolun, I. Pfeifer, A. G. So, J. W. Mellors, and W. A. Scott. 2002. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:1540-1545.
45. Meyer, P. R., A. J. Smith, S. E. Matsuura, and W. A. Scott. 2004. Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J. Biol. Chem. 279: 45389-45398.
46. Morris, M. C., C. Berducou, J. Mery, F. Heitz, and G. Divita. 1999. The thumb domain of the p51-subunit is essential for activation of HIV reverse transcriptase. Biochemistry 38:15097-15103.
47. Naeger, L. K., N. A. Margot, and M. D. Miller. 2002. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46:2179-2184.
48. Nikolenko, G. N., K. A. Delviks-Frankenberry, S. Palmer, F. Maldarelli, M. J. Fivash, Jr., J. M. Coffin, and V. K. Pathak. 2007. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido- 3′-deoxythymidine resistance. Proc. Natl. Acad. Sci. U. S. A. 104:317-322.
49. Nikolenko, G. N., S. Palmer, F. Maldarelli, J. W. Mellors, J. M. Coffin, and V. K. Pathak. 2005. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. U. S. A. 102:2093-2098.
50. Olivares, I., A. Mulky, P. I. Boross, J. Tözsér, J. C. Kappes, C. López-Galíndez, and L. Menéndez-Arias. 2007. HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions. J. Mol. Biol. 372:369-381.
51. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
52. Powell, M. D., W. A. Beard, K. Bebenek, K. J. Howard, S. F. J. Le Grice, T. A. Darden, T. A. Kunkel, S. H. Wilson, and J. G. Levin. 1999. Residues in the αH and αI helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer. J. Biol. Chem. 274:19885-19893.
53. Puertas, M. C., M. J. Buzón, A. Artese, S. Alcaro, L. Menéndez-Arias, C. F. Perno, B. Clotet, F. Ceccherini-Silberstein, and J. Martinez-Picado. 2009. Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility. J. Virol. 83:7434-7439.
54. Radzio, J., S.-H. Yap, G. Tachedjian, and N. Sluis-Cremer. 2010. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. AIDS 24:659-667.
55. Ray, A. S., A. Basavapathruni, and K. S. Anderson. 2002. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J. Biol. Chem. 277:40479-40490.
56. Ray, A. S., E. Murakami, A. Basavapathruni, J. A. Vaccaro, D. Ulrich, C. K. Chu, R. F. Schinazi, and K. S. Anderson. 2003. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 42:8831-8841.
57. Ray, A. S., E. Murakami, C. N. Peterson, J. Shi, R. F. Schinazi, and K. S. Anderson. 2002. Interactions of enantiomers of 2′,3′-didehydro- 2′,3′-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antiviral Res. 56:189-205.
58. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
59. Sarafianos, S. G., A. D. Clark, Jr., K. Das, S. Tuske, J. J. Birktoft, P. Ilankumaran, A. R. Ramesha, J. M. Sayer, D. M. Jerina, P. L. Boyer, S. H. Hughes, and E. Arnold. 2002. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21:6614-6624.
60. Sarafianos, S. G., K. Das, A. D. Clark, Jr., J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc. Natl. Acad. Sci. U. S. A. 96:10027-10032.
61. Sarafianos, S. G., K. Das, C. Tantillo, A. D. Clark, Jr., J. Ding, J. M. Whitcomb, P. L. Boyer, S. H. Hughes, and E. Arnold. 2001. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA: DNA. EMBO J. 20:1449-1461.
62. Sarafianos, S. G., B. Marchand, K. Das, D. M. Himmel, M. A. Parniak, S. H. Hughes, and E. Arnold. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385:693-713.
63. Schinazi, R. F., B. Hernandez-Santiago, and S. J. Hurwitz. 2006. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res. 71:322-334.
64. Sluis-Cremer, N., C.-W. Sheen, S. Zelina, P. S. A. Torres, U. M. Parikh, and J. W. Mellors. 2007. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 51:48-53.
65. Smith, A. J., and W. A. Scott. 2006. The influence of natural substrates and inhibitors on the nucleotide-dependent excision activity of HIV-1 reverse transcriptase in the infected cell. Curr. Pharm. Des. 12:1827-1841.
66. Svicher, V., T. Sing, M. M. Santoro, F. Forbici, F. Rodríguez- Barrios, A. Bertoli, N. Beerenwinkel, M. C. Bellocchi, F. Gago, A. d'Arminio Monforte, A. Antinori, T. Lengauer, F. Ceccherini-Silberstein, and C. F. Perno. 2006. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J. Virol. 80:7186-7198.
67. Tamura, K., J. Dudley, M. Nei, and S. Kumar. 2007. MEGA4: Molecular Evolutionary Genetic Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599.
68. Traut, T. W. 1994. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140:1-22.
69. Vivet-Boudou, V., J. Didierjean, C. Isel, and R. Marquet. 2006. Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell. Mol. Life Sci. 63:163-186.
70. Wang, J., S. J. Smerdon, J. Jäger, L. A. Kohlstaedt, P. A. Rice, J. M. Friedman, and T. A. Steitz. 1994. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc. Natl. Acad. Sci. U. S. A. 91:7242-7246.
71. Wang, Y.-X., H.-J. Zhang, J. Xu, B.-J. Zheng, and Y.-M. Wen. 2008. Mutational analysis of the "turn" of helix clamp motif of HIV-1 reverse transcriptase. Biochem. Biophys. Res. Commun. 377:915-920.
72. Waters, J. M., W. O'Neal, K. L. White, C. Wakeford, E. B. Lansdon, J. Harris, E. S. Svarovskaia, M. D. Miller, and K. Borroto-Esoda. 2009. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir. Ther. 14:231-239.
73. White, K. L., J. M. Chen, J. Y. Feng, N. A. Margot, J. K. Ly, A. S. Ray, H. L. MacArthur, M. J. McDermott, S. Swaminathan, and M. D. Miller. 2006. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir. Ther. 11:155-163.
74. Yap, S.-H., C.-W. Sheen, J. Fahey, M. Zanin, D. Tyssen, V. D. Lima, B. Wynhoven, M. Kuiper, N. Sluis-Cremer, P. R. Harrigan, and G. Tachedjian. 2007. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 4:e335.
75. Zelina, S., C.-W. Sheen, J. Radzio, J. W. Mellors, and N. Sluis-Cremer. 2008. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob. Agents Chemother. 52:157-163.